PRKACA and hepatocellular carcinoma: The DNAJB1-PRKACA fusion transcript was recently detected as the oncogenic driver of tumor pathogenesis in almost 100% of FL-HCC patients and thus represents an attractive target for the development of novel therapies for this devastating tumor disease (21–24).